UK’s life sciences sector continues to attract talent despite Brexit fear
The largest area of growth has been within biotechnology companies, where job openings increased by 35%.
Despite the on-going political and economic turmoil, demand for professionals to work within the UK’s life sciences sector increased by 25% in 2019, according to data from the Association of Professional Staffing Companies (APSCo) and business intelligence specialist, Vacancysoft.
The research also revealed that, while pharmaceutical firms continue to provide the lion’s share of professional opportunities, the largest area of growth has been within biotechnology companies, where job openings increased by 35%. Demand for professionals in clinical research organisations was also high, rising by 25% year-on-year.
In terms of function, R&D remains the strongest area for hiring, with vacancies up by 31% since 2018. Demand for quality assurance specialists was also notable, rising by 28%. By specialist role, clinical researchers were noted as a fast growth profession, increasing by 25% within clinical research organisations and 10% across Big Pharma.
South East England is the most dominant region for hiring life sciences professionals, accounting for 37% of all vacancies in the UK in 2019. Since 2018, job openings in the region have increased by 22%. In London, vacancies rose by 30% over the same period and now account for 18% of total roles. While accounting for a smaller proportion of overall vacancies, the East Midlands, Yorkshire & the Humber, South West England and North East England all noted 50%+ year-on-year growth in demand for professionals to work in the sector.
Research organisation, Covance, is now the largest single hirer of life sciences professionals in the UK, with vacancies up by 111% year-on-year in 2019. PRA Health Sciences, Envigo and AstraZeneca are also major players, with vacancies at these firm increasing by 210%, 71% and 21%, respectively.
Ann Swain, Chief Executive of APSCo, commented: “The UK life sciences sector is the most productive in the G7, and it’s encouraging to see that the government is fully committed to supporting its growth and by default, jobs in the sector. There are ambitious plans in the pipeline - as outlined in Sir John Bell’s Life Sciences Industrial Strategy - which focus on developing cutting-edge technology and new innovations along with £1.2 billion of new investment that will further strengthen the UK as a world-leading science base.”
James Chaplin, CEO of Vacancysoft, added: “The life sciences sector in the UK continues to go from strength to strength, and is undoubtedly a critical part of the nation’s economic strength. It contributes over £70 billion a year to the economy and supports 240,000 jobs - with no signs of slowing down. It is also unsurprising to see that R&D continues to be one of the strongest areas for hiring, as the government has recently announced that it is committed to raising the intensity of R&D spend to reach 2.4% of GDP in the UK by 2027.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance